OMER
Omeros Corporation NASDAQ Listed Oct 8, 2009$10.28
+6.64%
vs $9.64
Mkt Cap $652.9M
52w Low $2.97
51.4% of range
52w High $17.18
50d MA $12.22
200d MA $10.11
P/E (TTM)
-195.1x
EV/EBITDA
—
P/B
—
Debt/Equity
-2.0x
ROE
2.8%
P/FCF
-5.6x
RSI (14)
42.10
ATR (14)
$0.78
Beta
2.53
50d MA
$12.22
200d MA
$10.11
Avg Volume
2.0M
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
The Omeros Building · Seattle, WA 98119 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.55 | 3.14 | +670.9% | 10.56 | +7.2% | +14.4% | -9.8% | -0.1% | +0.8% | +4.8% | — |
| Nov 13, 2025 | AMC | -0.58 | -0.19 | +67.2% | 6.28 | +5.7% | +25.3% | +15.4% | -6.4% | -3.3% | +0.1% | — |
| Aug 14, 2025 | AMC | -0.55 | -0.53 | +3.6% | 4.12 | +2.7% | +7.0% | -4.3% | +3.3% | -3.9% | +6.9% | — |
| May 15, 2025 | AMC | -0.57 | -0.65 | -14.0% | 3.95 | -1.3% | -18.5% | +3.1% | -0.9% | -5.5% | +3.5% | — |
| Mar 31, 2025 | AMC | -0.78 | -0.63 | +19.2% | 8.22 | +11.4% | -3.8% | +1.3% | -8.1% | -4.1% | -2.3% | — |
| Nov 13, 2024 | AMC | -0.70 | -0.64 | +8.6% | 4.19 | +5.5% | +65.9% | -2.9% | -12.3% | +1.9% | +0.0% | — |
| Aug 7, 2024 | AMC | -1.14 | -1.12 | +1.8% | 4.15 | -0.5% | -5.8% | +5.4% | +3.9% | -3.5% | -0.5% | — |
| May 15, 2024 | AMC | -0.58 | -0.74 | -27.6% | 4.17 | -24.9% | -20.6% | +4.2% | -4.3% | +1.8% | +1.8% | — |
| Apr 1, 2024 | AMC | -0.56 | -0.63 | -12.5% | 3.19 | -8.5% | -4.4% | +3.3% | -1.0% | +9.9% | -0.3% | — |
| Nov 9, 2023 | AMC | -0.62 | -0.82 | -32.3% | 1.26 | -4.8% | -0.8% | +12.0% | +6.4% | +1.3% | +0.0% | — |
| Aug 9, 2023 | AMC | -0.60 | -0.70 | -16.7% | 4.33 | -0.7% | -3.0% | +2.4% | -7.2% | -6.5% | -5.1% | — |
| May 9, 2023 | AMC | -0.55 | -0.63 | -14.5% | 5.00 | +4.0% | +21.2% | -9.7% | +4.4% | -5.6% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | D. Boral Capital | Maintains | Buy → Buy | — | $13.47 | $13.40 | -0.5% | -1.6% | +0.8% | +1.1% | +0.1% | +8.9% |
| Jan 27 | D. Boral Capital | Maintains | Buy → Buy | — | $11.53 | $11.53 | +0.0% | +9.9% | -6.8% | +1.2% | -2.2% | +0.3% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.09 | $14.52 | +3.1% | -4.5% | -7.1% | +2.6% | -1.6% | +3.6% |
| Jan 8 | D. Boral Capital | Maintains | Buy → Buy | — | $14.09 | $14.52 | +3.1% | -4.5% | -7.1% | +2.6% | -1.6% | +3.6% |
| Dec 24 | D. Boral Capital | Maintains | Buy → Buy | — | $8.75 | $16.44 | +87.9% | +75.5% | +2.3% | +5.5% | +2.4% | +1.3% |
| Dec 1 | D. Boral Capital | Maintains | Buy → Buy | — | $9.69 | $9.83 | +1.4% | -0.1% | -2.6% | +12.6% | +3.9% | -1.6% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $6.28 | $6.64 | +5.7% | +25.3% | +15.4% | -6.4% | -3.3% | +0.1% |
| Oct 16 | D. Boral Capital | Maintains | Buy → Buy | — | $10.42 | $9.15 | -12.2% | -5.7% | -17.5% | +1.7% | -4.6% | -1.7% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.10 | $11.59 | +182.7% | +154.1% | -5.7% | -17.5% | +1.7% | -4.6% |
| Oct 15 | WBB Securities | Maintains | Strong Buy → Strong Buy | — | $4.10 | $11.59 | +182.7% | +154.1% | -5.7% | -17.5% | +1.7% | -4.6% |
| Oct 15 | Needham | Maintains | Hold → Hold | — | $4.10 | $11.59 | +182.7% | +154.1% | -5.7% | -17.5% | +1.7% | -4.6% |
| Oct 15 | D. Boral Capital | Maintains | Buy → Buy | — | $4.10 | $11.59 | +182.7% | +154.1% | -5.7% | -17.5% | +1.7% | -4.6% |
| Sep 3 | D. Boral Capital | Maintains | Buy → Buy | — | $4.29 | $4.24 | -1.2% | -2.6% | +0.0% | -0.2% | +1.0% | +1.2% |
| Aug 15 | D. Boral Capital | Maintains | Buy → Buy | — | $4.12 | $4.23 | +2.7% | +7.0% | -4.3% | +3.3% | -3.9% | +6.9% |
| Aug 15 | Needham | Maintains | Hold → Hold | — | $4.12 | $4.23 | +2.7% | +7.0% | -4.3% | +3.3% | -3.9% | +6.9% |
| Jul 25 | D. Boral Capital | Maintains | Buy → Buy | — | $3.59 | $3.86 | +7.5% | +6.7% | +8.4% | -4.3% | -3.0% | +0.5% |
| Jun 30 | D. Boral Capital | Maintains | Buy → Buy | — | $3.20 | $3.20 | +0.0% | -6.2% | -1.0% | +4.0% | +3.6% | -3.8% |
| May 16 | Needham | Maintains | Hold → Hold | — | $3.95 | $3.90 | -1.3% | -18.5% | +3.1% | -0.9% | -5.5% | +3.5% |
| May 13 | D. Boral Capital | Maintains | Buy → Buy | — | $3.80 | $4.22 | +11.1% | +16.6% | -11.3% | +0.5% | -18.5% | +3.1% |
| May 7 | D. Boral Capital | Maintains | Buy → Buy | — | $6.34 | $6.33 | -0.2% | +0.2% | -0.6% | -2.1% | -38.5% | +16.6% |
| Apr 11 | D. Boral Capital | Maintains | Buy → Buy | — | $5.86 | $5.87 | +0.2% | +14.8% | +3.9% | -1.7% | -1.6% | +0.3% |
| Apr 1 | D. Boral Capital | Maintains | Buy → Buy | — | $8.22 | $9.16 | +11.4% | -3.8% | +1.3% | -8.1% | -4.1% | -2.3% |
| Apr 1 | Needham | Maintains | Hold → Hold | — | $8.22 | $9.16 | +11.4% | -3.8% | +1.3% | -8.1% | -4.1% | -2.3% |
| Mar 21 | D. Boral Capital | Maintains | Buy → Buy | — | $9.10 | $8.97 | -1.4% | +0.0% | -0.9% | +1.6% | -7.0% | +4.7% |
| Feb 20 | D. Boral Capital | Maintains | Buy → Buy | — | $9.25 | $9.54 | +3.1% | +3.9% | -4.5% | -5.4% | -2.6% | +3.6% |
| Jan 17 | Needham | Maintains | Hold → Hold | — | $9.18 | $9.18 | +0.0% | +1.6% | -1.9% | +1.5% | -3.0% | -7.1% |
| Jan 16 | D. Boral Capital | Maintains | Buy → Buy | — | $8.90 | $9.11 | +2.4% | +3.1% | +1.6% | -1.9% | +1.5% | -3.0% |
| Dec 19 | Needham | Maintains | Hold → Hold | — | $7.46 | $9.71 | +30.2% | +37.3% | +0.7% | -1.9% | -1.1% | +4.6% |
| Nov 10 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $1.26 | $1.20 | -4.8% | -0.8% | +12.0% | +6.4% | +1.3% | +0.0% |
| Dec 8 | UBS | Downgrade | Buy → Neutral | — | $2.22 | $2.10 | -5.4% | -0.9% | -6.4% | +3.4% | +5.6% | -12.0% |
| Nov 8 | BofA Securities | Downgrade | Neutral → Underperform | — | $3.28 | $3.34 | +1.8% | -2.4% | -11.9% | -5.7% | +3.0% | +4.0% |
| Jun 8 | BofA Securities | Downgrade | Buy → Neutral | — | $2.42 | $2.30 | -5.0% | -9.9% | -1.8% | -2.3% | -3.3% | -3.5% |
| Oct 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.67 | $5.82 | +2.6% | +9.7% | +2.9% | +0.9% | +0.5% | -2.6% |
| Oct 8 | JP Morgan | Downgrade | Neutral → Underweight | — | $7.43 | $7.09 | -4.6% | -9.8% | +6.9% | -0.6% | +3.7% | +4.7% |
| Oct 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.08 | $6.99 | -1.3% | +1.8% | +3.1% | -9.8% | +6.9% | -0.6% |
| Oct 4 | Maxim Group | Downgrade | Buy → Hold | — | $8.54 | $8.08 | -5.4% | -14.8% | -2.7% | +1.8% | +3.1% | -9.8% |
| Jun 18 | WBB Securities | Maintains | Strong Buy → Strong Buy | — | $14.97 | $15.19 | +1.5% | +0.6% | +1.7% | +0.9% | -0.1% | +0.6% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.65 | $18.65 | +0.0% | -2.7% | -0.6% | -0.3% | -0.4% | -1.4% |
| Feb 1 | UBS | Maintains | Buy → Buy | — | $19.46 | $19.88 | +2.2% | +5.1% | +3.0% | +2.9% | -0.1% | -2.4% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.46 | $19.87 | +2.1% | -2.4% | -1.9% | +5.6% | -0.9% | -1.4% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.29 | $14.30 | +0.1% | +1.6% | +0.0% | +3.7% | +5.0% | +1.3% |
| Oct 20 | BofA Securities | Maintains | Buy → Buy | — | $11.08 | $11.71 | +5.7% | +1.6% | -1.0% | -0.9% | -3.5% | -4.1% |
| Sep 1 | Wedbush | Maintains | Neutral → Neutral | — | $11.95 | $11.86 | -0.8% | -9.3% | -2.6% | -2.3% | -3.1% | +6.0% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.95 | $12.85 | -0.8% | -3.9% | -3.2% | -2.2% | +1.9% | -2.5% |
| Dec 2 | H.C. Wainwright | Maintains | Buy → Buy | — | $14.80 | $14.59 | -1.4% | -2.4% | -0.5% | +6.1% | -12.7% | -1.1% |
| May 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.62 | $19.46 | -0.8% | -0.1% | -8.8% | +2.9% | +0.9% | +4.1% |
| Aug 10 | Maxim Group | Maintains | Buy → Buy | — | $21.70 | $22.28 | +2.7% | -18.3% | +8.2% | +7.5% | -2.3% | +1.9% |
| May 17 | Wedbush | Maintains | Neutral → Neutral | — | $20.01 | $19.90 | -0.5% | +1.2% | -0.7% | +3.3% | +0.0% | -4.8% |
| Mar 23 | Maxim Group | Maintains | Buy → Buy | — | $15.75 | $14.75 | -6.3% | -10.5% | -12.8% | -0.3% | -2.7% | -6.2% |
| Mar 23 | Wedbush | Downgrade | Outperform → Neutral | — | $15.75 | $14.75 | -6.3% | -10.5% | -12.8% | -0.3% | -2.7% | -6.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Cable Thomas J.Dir | — | Sell | 7,500 | $11.61 | $87K | 35,067 | +0.72% | -0.97% |
8-K · 8.01
!! High
Omeros Corporation -- 8-K 8.01: Material Event / Announcement
Jun 18
8-K · 8.01
!! High
Kyverna Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Eli Lilly acquired Kyverna Therapeutics for an undisclosed amount, expanding its immunology portfolio with Kyverna's cell therapy candidates.
May 4
8-K · 5.02
!!! Very High
Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change
Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.
Apr 21
8-K
Unknown — 8-K Filing
Omeros reported full-year 2025 financial results, signaling operational updates investors should monitor for revenue trends, profitability, and pipeline progress affecting future growth prospects.
Mar 31
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 2,983,259 | $32M | New | Mar 2026 |
| 2 | Ubs Group Ag | 2,340,731 | $25M | Added | Mar 2026 |
| 3 | Morgan Stanley | 772,304 | $13M | Reduced | Dec 2025 |
| 4 | Jane Street Group, Llc | 463,622 | $8M | Added | Dec 2025 |
| 5 | Vanguard Portfolio Management Llc | 718,675 | $8M | New | Mar 2026 |
| 6 | Bank Of Montreal /can/ | 568,426 | $6M | Reduced | Mar 2026 |
| 7 | Northern Trust Corp | 563,867 | $6M | Added | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 485,030 | $5M | Reduced | Mar 2026 |
| 9 | Millennium Management | 410,609 | $4M | Reduced | Mar 2026 |
| 10 | Clutterbuck Capital Management Llc | 300,000 | $3M | Added | Mar 2026 |
| 11 | Itau Unibanco Holding S.a. | 180,000 | $3M | — | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 286,474 | $3M | Reduced | Mar 2026 |
| 13 | Citadel Advisors Llc | 260,048 | $3M | Added | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 204,805 | $2M | Reduced | Mar 2026 |
| 15 | Invesco Ltd. | 180,629 | $2M | Added | Mar 2026 |
| 16 | Hightower Advisors, Llc | 104,059 | $2M | Added | Dec 2025 |
| 17 | Bank Of New York Mellon Corp | 166,246 | $2M | — | Mar 2026 |
| 18 | Nuveen, Llc | 154,201 | $2M | Added | Mar 2026 |
| 19 | Wells Fargo & Company/mn | 118,343 | $1M | New | Mar 2026 |
| 20 | Marshall Wace, Llp | 83,682 | $884K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$652.9M
Enterprise Value
$689.6M
P/E (TTM)
-195.07x
Forward P/E
—
PEG Ratio
3.32x
P/B
—
P/S
—
P/FCF
-5.62x
EV/EBITDA
—
Shares Out
63.5M
Financials (TTM)
Revenue
$0
Net Income
-$3.4M
EBITDA
-$121.8M
Free Cash Flow
-$116.2M
Op Cash Flow
-$116.1M
EPS Basic
$-0.05
EPS Diluted
$-0.05
EPS Forward
$-0.79
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$325.6M
Total Liab.
$446.9M
Total Equity
-$121.2M
Cash
$171.8M
LT Debt
$208.5M
Book Value/Sh
$-1.91
Debt/Equity
-1.97x
Current Ratio
2.76
Quick Ratio
2.76
Returns & Growth
ROE
2.8%
ROA
-1.0%
ROIC
-45.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+98.0%
Price Returns
2W
-16.9%
1M
-24.4%
3M
-8.4%
6M
+13.9%
12M
+257.3%
Technicals
52W High
$17.18
52W Low
$2.97
50d MA
$12.22
200d MA
$10.11
RSI (14)
42.10
ATR (14)
$0.78
Beta
2.53
Avg Volume
2.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$40.00
High
$40.00
Low
$40.00
Median
$40.00
Data updated apr 26, 2026 5:22pm
· Source: financialmodelingprep.com